Comparison of intravenous tranexamic acid and intravenous fibrinogen on bleeding control in posterior lumbar spine fusion surgery.

Phase 3

Conditions: umbar Discopathy.
Intervertebral disc disorders with myelopathy, thoracolumbar region
M51.05

Registration Number: IRCT20210415050983N4

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 40

Inclusion Criteria

No history of drug allergy
No history of thromboembolism and coagulation disorders
No history of liver or kidney failure
No history of heart disease and hypertension
ASA I , II
Patient consent to participate in the study

Exclusion Criteria

use of anticoagulants
History of blood disorders and coagulopathy
History of liver disease
History of chronic kidney disease and creatinine greater than 2mg / dl
History of thromboembolic events at any time

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Determination of intraoperative bleeding in groups receiving tranexamic acid ,fibrinogen and control group. Timepoint: End of surgery. Method of measurement: Bleeding volume during field operation, blood gases, suction.;Determining the duration of surgery in the groups receiving tranexamic acid ,fibrinogen and the control group. Timepoint: End of surgery. Method of measurement: hours / minutes.;Amount of blood and blood products injected. Timepoint: End of surgery. Method of measurement: The number of units to be injected.

Secondary Outcome Measures

Name	Time	Method
Determining the duration of surgery in the groups receiving tranexamic acid ,fibrinogen and the control group. Timepoint: End of surgery. Method of measurement: hours / minutes.;Determination of recovery time after reverse dose injection in groups receiving tranexamic acid ,fibrinogen and control group. Timepoint: End of surgery. Method of measurement: hours / minutes.;Determining the length of stay in the intensive care unit in the groups receiving tranexamic acid ,fibrinogen and the control group. Timepoint: End of surgery. Method of measurement: hours / minutes.